![]() |
市場調查報告書
商品編碼
1519735
2024-2032 年銀傷口敷料市場報告(按類型、疾病、最終用戶和地區)Silver Wound Dressing Market Report by Type, Disease, End User, and Region 2024-2032 |
IMARC Group年,全球銀傷口敷料市場規模達到 9.701 億美元。
銀傷口敷料是指向傷口釋放穩定量的銀以提供抗菌和抗菌作用的局部傷口護理產品。它們以屏障層、木炭布敷料、泡棉敷料和水膠體的形式廣泛使用。銀敷料可用作主要或次要敷料,以處理急性和慢性傷口(例如手術傷口、燒傷、壓瘡、腿部潰瘍和糖尿病足潰瘍)中的少量、中度或大量滲出液。它們還可以在壓迫下或與選定的局部和輔助療法一起使用,以減少細菌負荷、抑制滲出物並改善傷口肉芽組織的外觀。近年來,銀傷口敷料在醫療保健產業中廣受歡迎,用於治療局部感染或生物負荷或有局部感染或生物負荷風險的急性或慢性傷口。
銀傷口敷料有助於預防和減少感染,提供廣泛的抗菌活性,並改變傷口內的金屬蛋白酶。因此,銀傷口敷料正在迅速取代傳統的傷口護理和閉合產品,這是推動市場成長的主要因素。除此之外,慢性傷口和燒傷的發生率不斷上升,以及人們對先進傷口護理治療的認知不斷增強,都刺激了對銀傷口敷料的需求。此外,癌症、糖尿病和心血管疾病(CVD)等慢性病的盛行率顯著增加。同時,越來越多的接受手術的患者鼓勵採用銀傷口敷料,以防止手術部位感染並促進傷口更快癒合。此外,一些主要參與者正在投入大量資金推出新型創新銀傷口敷料變體,以擴大其產品組合併獲得競爭優勢。其他因素,包括家庭醫療保健的新興趨勢、道路事故案件的增加、人口老化、醫療基礎設施的改善、技術進步以及廣泛的研發(R&D)活動,也為市場成長提供了積極的推動力。
The global silver wound dressing market size reached US$ 970.1 Million in 2023. Looking forward, IMARC Group expects the market to reach US$ 1,386.7 Million by 2032, exhibiting a growth rate (CAGR) of 4% during 2024-2032.
Silver wound dressings refer to topical wound care products that release a steady amount of silver to the wound to provide antimicrobial and antibacterial action. They are widely available in the form of barrier layers, charcoal cloth dressings, foam dressings, and hydrocolloids. Silver dressings can be used as primary or secondary dressings to manage minimal, moderate, or heavy exudate in acute and chronic wounds, such as surgical wounds, burns, pressure ulcers, leg ulcers, and diabetic foot ulcers. They can also be utilized under compression or with select topical and adjunctive therapies to reduce the bacterial load, contain exudate, and improve the appearance of the wound's granulation tissue. In recent years, silver wound dressings have gained immense popularity in the healthcare industry to treat acute or chronic wounds with or at risk of local infection or bioburden.
Silver wound dressings help prevent and reduce infections, provide a wide range of antimicrobial activity, and alter metalloproteinases within wounds. As a result, silver wound dressings are rapidly replacing traditional wound care and closure products, which represents the primary factor driving the market growth. Besides this, the rising incidences of chronic wounds and burns and the growing awareness regarding advanced wound care treatment are catalyzing the demand for silver wound dressings. Additionally, there has been a significant increase in the prevalence of chronic conditions, such as cancer, diabetes, and cardiovascular diseases (CVDs). Along with this, the increasing number of patients undergoing surgeries is encouraging the adoption of silver wound dressings to prevent surgical site infections and promote faster wound healing. Furthermore, several key players are making heavy investments to launch new and innovative silver wound dressing variants to expand their product portfolio and gain a competitive edge. Other factors, including the emerging trend of home healthcare, rising cases of road accidents, aging population, improving healthcare infrastructure, technological advancements, and extensive research and development (R&D) activities, are also providing a positive thrust to the market growth.
IMARC Group provides an analysis of the key trends in each sub-segment of the global silver wound dressing market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on type, disease and end user.
Hydrofiber Silver Dressings
Nanocrystalline Silver Dressing
Silver Plated Nylon Fiber Dressing
Silver Nitrate Dressing
Silver Alginate Dressing
Others
Ulcers
Burns
Cuts and Lacerations
Others
Inpatient Facilities
Outpatient Facilities
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
The competitive landscape of the industry has also been examined along with the profiles of the key players being 3M Company, Advanced Medical Solutions Group plc, B. Braun Melsungen AG, Cardinal Health Inc., Coloplast A/S, ConvaTec Group plc, Ferris Mfg. Corp., Hollister Incorporated, Integra LifeSciences, Medline Industries LP, Molnlycke Health Care AB and Smith & Nephew plc.